儿童分化型甲状腺癌的单点突变研究
该研究对1998-2015年89例≤18岁儿童及青少年分化型甲状腺癌(DTC)进行单点突变检测,聚焦72例经典型乳头状甲状腺癌(PTC)和7例滤泡型PTC。结果显示BRAFV600E突变见于19/72(26.4%)经典型PTC,滤泡型PTC中未见;BRAFV600E突变与性别、腺外侵犯、多灶性、血管侵犯、淋巴结或远处转移及持续/复发疾病均无显著关联。PIK3CA、PTEN、NRAS 61及TERT C228T突变罕见。
要点
- 儿童DTC中BRAFV600E突变见于19/72(26.4%)经典型PTC,7例滤泡型PTC均未检出。
- BRAFV600E突变与性别、腺外侵犯、多灶性、血管侵犯、淋巴结或远处转移及持续/复发疾病无显著关联。
- PIK3CA、PTEN、NRAS 61及TERT C228T突变在儿童DTC中罕见。
核心结论
- 儿童DTC中BRAFV600E突变患病率显著低于成人DTC,且该突变与PTC的组织病理学特征及结局无关联。
- PIK3CA、PTEN、NRAS 61和TERT C228T突变罕见。
研究设计与样本
- 研究纳入1998-2015年间连续收治的89例儿童及青少年(≤18岁)DTC病例,排除罕见变异型,聚焦72例(91.1%)经典型PTC和7例(8.9%)滤泡型PTC;其中女性68例(86.1%),男性11例(13.9%),中位年龄15.5岁(范围8-18岁)。
- 从病历获取临床和病理数据,从石蜡包埋肿瘤组织提取DNA,进行PCR扩增和直接测序,检测BRAF、HRAS、KRAS、NRAS、PIK3CA、PTEN和TERT的单点突变。
主要发现
- BRAFV600E突变见于19/72(26.4%)经典型PTC样本,7例滤泡型PTC中均未检出。
- 其他突变包括:TERT C228T 1/78(1.3%)成功扩增的肿瘤样本;NRAS 61 2/79(2.5%)(c.181C>A和c.182A>G);PIK3CA外显子9 1/73(1.4%)(一个肿瘤中c.1589A>G和c.1598C>T);PIK3CA外显子20 1/79(1.3%)(c.2951G>A);PTEN外显子5 1/74(1.4%)(c.295G>A)。
- HRAS、KRAS、NRAS12、PTEN外显子6、7、8及TERT C250T未发现突变。
- BRAFV600E突变与性别、腺外侵犯、肿瘤多灶性、血管侵犯、淋巴结或远处转移及持续/复发疾病之间均无显著关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Differentiated thyroid cancer (DTC) is rare in children. Previous studies have suggested that it has different clinicopathologic features and mutation profiles compared with adult DTC. However, those studies focused on a single or limited number of gene mutations. This study comprehensively investigated a large series of pediatric DTC for single point mutations in BRAF, HRAS, KRAS, NRAS, PIK3CA, PTEN, and TERT. It also analyzed associations between clinicopathologic features and the BRAFV600E mutation. PATIENTS AND METHODS: Eighty-nine consecutive cases seen in children and adolescents (≤18 years) during 1998-2015 were identified. Rare variants of DTC were excluded, and the study focused on 72 (91.1%) classical papillary thyroid carcinoma (PTC) and seven (8.9%) follicular variant PTC. These included 68 (86.1%) females and 11 (13.9%) males, with a median age of 15.5 years (range 8-18 years). The clinical and histopathological data were obtained from medical records. DNA was extracted from paraffin-embedded tumor tissue, and was PCR-amplified and directly sequenced. RESULTS: Mutations detected included BRAFV600E in 19/72 (26.4%) classical PTC samples, and in none of seven follicular variant PTC. Other mutations included: 1/78 (1.3%) successfully amplified tumor samples with TERT C228T; 2/79 (2.5%) NRAS 61 (c.181C>A and c.182A>G); 1/73 (1.4%) PIK3CA exon 9 (c.1589A>G and c.1598C>T in one tumor); 1/79 (1.3%) PIK3CA exon 20 (c.2951G>A); and 1/74 (1.4%) PTEN exon 5 (c.295G>A). No mutation was found in HRAS, KRAS, NRAS12, PTEN exons 6, 7, and 8, and TERT C250T. No significant association was found between BRAFV600E mutation and sex, extrathyroidal invasion, tumor multifocality, vascular invasion, lymph node or distant metastases, and persistent/recurrent disease. CONCLUSIONS: In pediatric DTC, the prevalence of the BRAFV600E mutation is significantly less common compared with adult DTC, and there is no association between this mutation and the histopathological features and outcome of PTC. PIK3CA, PTEN, NRAS 61, and TERT C228T mutations are rare.
引用
- Alzahrani AS, Murugan AK, Qasem E, et al. Single Point Mutations in Pediatric Differentiated Thyroid Cancer. Thyroid. 2016. PMID: 27824297. doi:10.1089/thy.2016.0339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。